CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,688,348 | -27.5% | 180,305 | -46.8% | 1.24% | -26.7% |
| Q2 2023 | $3,710,320 | +22.3% | 338,842 | -2.6% | 1.70% | -31.3% |
| Q1 2023 | $3,032,694 | +22.3% | 347,786 | -12.0% | 2.47% | +67.9% |
| Q4 2022 | $2,478,732 | +79.1% | 395,332 | 0.0% | 1.47% | +86.2% |
| Q3 2022 | $1,384,000 | +18.7% | 395,332 | 0.0% | 0.79% | +12.2% |
| Q2 2022 | $1,166,000 | +80.8% | 395,332 | +90.7% | 0.70% | +71.7% |
| Q1 2022 | $645,000 | -3.6% | 207,307 | +77.9% | 0.41% | -4.0% |
| Q4 2020 | $669,000 | – | 116,519 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,653,495 | $10,367,414 | 8.97% |
| Versant Venture Management, LLC | 543,753 | $3,409,330 | 7.06% |
| TCG Crossover Management, LLC | 5,905,400 | $37,026,858 | 6.54% |
| COMMODORE CAPITAL LP | 5,738,500 | $35,980 | 5.42% |
| Foresite Capital Management IV, LLC | 1,787,094 | $11,205,079 | 4.79% |
| Saturn V Capital Management LP | 1,611,778 | $5,718,432 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 1,015,000 | $6,364,050 | 3.92% |
| Altium Capital Management LP | 1,025,000 | $6,426,750 | 3.27% |
| Affinity Asset Advisors, LLC | 1,143,531 | $7,169,939 | 2.81% |
| GREAT POINT PARTNERS LLC | 1,550,000 | $9,718,500 | 1.90% |